Is Gujarat Themis Biosyn the Best Stock in Its Sector? A Look at the Numbers
- September 28, 2026
- Posted by: Chaitanya Auti
- Category: Market
Gujarat Themis Biosyn CMP Rs 412 (28 Sep 2026). Market cap Rs 5,431 Cr. ROE 16.22%. P/E 111.58x versus Industry P/E 51.67x.
Quick Answer
Gujarat Themis Biosyn is one of the names investors compare when screening the Healthcare sector, built on a 16.22% return on equity and a P/E of 111.58x against an Industry P/E of 51.67x. Whether Gujarat Themis Biosyn is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.
Is Gujarat Themis Biosyn the best stock in its sector? The stock trades on the NSE at Rs 412 as of 28 September 2026, within its 52-week range of Rs 225.05 to Rs 479.00. Gujarat Themis Biosyn Ltd manufactures fermentation-based active pharmaceutical ingredients and intermediates, including rifamycin-based products.
Gujarat Themis Biosyn sits in the Healthcare sector, and its 16.22% ROE and 111.58x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Gujarat Themis Biosyn
Gujarat Themis Biosyn Ltd manufactures fermentation-based active pharmaceutical ingredients and intermediates, including rifamycin-based products. The stock has rallied strongly from its 52-week low over the past year. At a market capitalisation of Rs 5,431 Cr, it is tracked as part of the Healthcare sector on Univest.
Is Gujarat Themis Biosyn the Best Stock in Its Sector?
Gujarat Themis Biosyn makes its case as the best stock in its sector primarily on return on equity and balance sheet strength, combining a 16.22% ROE with a 111.58x P/E against the sector’s 51.67x Industry P/E. Gujarat Themis Biosyn’s 111.58x P/E is more than double the 51.67x Industry P/E, a rich valuation that rests on future growth rather than current earnings, even with a solid 16.22% ROE.
| Metric | Gujarat Themis Biosyn |
|---|---|
| CMP (NSE) | Rs 411.65 |
| 52-Week High / Low | Rs 479.00 / Rs 225.05 |
| Market Cap | Rs 5,431 Cr |
| P/E (TTM) vs Industry P/E | 111.58x vs 51.67x |
| P/B | 5.23 |
| ROE | 16.22% |
| EPS (TTM) | Rs 3.74 |
| Dividend Yield | 0.13% |
| Debt to Equity | 0.56 |
Compare Gujarat Themis Biosyn Against Other Healthcare Sector Stocks
How Gujarat Themis Biosyn Compares Against Its Healthcare Sector Peers
The table below sets Gujarat Themis Biosyn against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Gujarat Themis Biosyn | 5,431 | 111.58 | 16.22% | 0.56 |
| Blue Jet Healthcare | 11,075 | 47.15 | 18.22% | 0.03 |
| Gufic Biosciences | 4,224 | 57.55 | 9.66% | 0.61 |
| Peer average (2 companies) | – | 52.35 | 13.94% | 0.32 |
Against this peer set, Gujarat Themis Biosyn’s 16.22% ROE is above the 13.94% peer average, and its P/E of 111.58x runs above the peer average of 52.35x. Gujarat Themis Biosyn’s 111.58x P/E is more than double the 51.67x Industry P/E, a rich valuation that rests on future growth rather than current earnings, even with a solid 16.22% ROE.
What Makes Gujarat Themis Biosyn Worth Watching in Healthcare
- Strong ROE: A 16.22% ROE is a healthy figure for an API manufacturer.
- Fermentation-based API specialisation: Focusing on fermentation-based APIs and intermediates gives Gujarat Themis Biosyn a technically specialised product base.
- Strong recovery from its 52-week low: The share price is far above its 52-week low, so a good part of the improvement is already reflected in the price.
Gujarat Themis Biosyn Valuation: Is It Justified?
Gujarat Themis Biosyn’s 111.58x P/E is more than double the 51.67x Industry P/E, a rich valuation that rests on future growth rather than current earnings, even with a solid 16.22% ROE. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is Godrej Agrovet the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Gujarat Themis Biosyn and other Healthcare sector stocks.
How to Track Gujarat Themis Biosyn Before You Invest
Before deciding whether Gujarat Themis Biosyn deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.
- Open the Univest Screener and search for Gujarat Themis Biosyn to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
- Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Gujarat Themis Biosyn earns a place in the best stock in its sector conversation on the strength of a 16.22% ROE and a P/E of 111.58x against a 51.67x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Gujarat Themis Biosyn the best stock in its sector?
Ans. Gujarat Themis Biosyn has a 16.22% ROE and trades at 111.58x P/E against a 51.67x Industry P/E, and compares above the peer average ROE of 13.94% in this article’s named comparison, so the answer depends on what an investor is prioritising.
What is the current share price of Gujarat Themis Biosyn?
Ans. Gujarat Themis Biosyn was trading at Rs 411.65 on the NSE as of 28 September 2026, within its 52-week range of Rs 225.05 to Rs 479.00.
What sector does Gujarat Themis Biosyn belong to?
Ans. Gujarat Themis Biosyn is classified under the Healthcare sector on Univest.
How does Gujarat Themis Biosyn compare to its sector peers on P/E?
Ans. Gujarat Themis Biosyn’s P/E of 111.58x is above the 52.35x average of the 2 named peers compared in this article.
What is Gujarat Themis Biosyn’s return on equity?
Ans. Gujarat Themis Biosyn reported a return on equity of 16.22%, which is above the 13.94% average of its named peers in this comparison.
Should I invest in Gujarat Themis Biosyn based on its sector position?
Ans. Gujarat Themis Biosyn’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.